|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Nisoldipine#Use in Specific Populations]] |
| {{Nisoldipine}}
| |
| {{CMG}}; {{AE}}:{{AK}}
| |
| | |
| '''''For patient information about Nisoldipine, click [[Nisoldipine (patient information)|here]].'''''
| |
| | |
| ==Drug Interactions==
| |
| | |
| A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of [[cimetidine]] 400 mg twice daily.[[Ranitidine]] 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15 - 20%). No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.
| |
| | |
| ===CYP3A4 inhibitors and inducers===
| |
| | |
| SULAR is substrate of CYP3A4 and coadministration of SULAR with any known inducer or inhibitor of CYP3A4 should be avoided in general.
| |
| Coadministration of phenytoin with a dose bioequivalent to 34 mg SULAR tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels. Coadministration of SULAR with [[phenytoin ]]should be avoided and alternative antihypertensive therapy should be considered. Pharmacokinetic interactions between nisoldipine and beta-blockers ([[atenolol]], [[propranolol]]) were variable and not significant. Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine. The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy. [[Quinidine]] at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration. Immediate release nisoldipine increased plasma quinidine concentrations by about 20%. This interaction was not accompanied by ECG changes and its clinical significance is not known. No significant interactions were found between nisoldipine and warfarin of digoxin.
| |
| {{Reflist|2}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |